Literature DB >> 33362547

Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer.

Jingwei Yao1,2, Kun Deng3, Jialu Huang3, Ruimin Zeng1, Jianhong Zuo1,3,2.   

Abstract

Tamoxifen is a drug commonly used in the treatment of breast cancer, especially for postmenopausal patients. However, its efficacy is limited by the development of drug resistance. Downregulation of estrogen receptor alpha (ERα) is an important mechanism of tamoxifen resistance. In recent years, with progress in research into the protective autophagy of drug-resistant cells and cell cycle regulators, major breakthroughs have been made in research on tamoxifen resistance. For a better understanding of the mechanism of tamoxifen resistance, protective autophagy, cell cycle regulators, and some transcription factors and enzymes regulating the expression of the estrogen receptor are summarized in this review. In addition, recent progress in reducing resistance to tamoxifen is reviewed. Finally, we discuss the possible research directions into tamoxifen resistance in the future to provide assistance for the clinical treatment of breast cancer.
Copyright © 2020 Yao, Deng, Huang, Zeng and Zuo.

Entities:  

Keywords:  autophagy; breast cancer; cell cycle regulators; resistance; tamoxifen

Year:  2020        PMID: 33362547      PMCID: PMC7758911          DOI: 10.3389/fphar.2020.592912

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  90 in total

1.  The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells.

Authors:  Mengjia He; Qianni Jin; Cong Chen; Yifeng Liu; Xiangsen Ye; Yulin Jiang; Feihu Ji; Husun Qian; Delu Gan; Shujun Yue; Wei Zhu; Tingmei Chen
Journal:  Oncogene       Date:  2019-04-09       Impact factor: 9.867

2.  Effect of aspirin use on neoadjuvant chemoradiotherapy for rectal cancer: a meta-analysis with trial sequential analysis.

Authors:  Bolin Wang; Yan Huang
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-23       Impact factor: 4.553

3.  LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.

Authors:  Anika Nagelkerke; Anieta M Sieuwerts; Johan Bussink; Fred C G J Sweep; Maxime P Look; John A Foekens; John W M Martens; Paul N Span
Journal:  Endocr Relat Cancer       Date:  2014-01-16       Impact factor: 5.678

4.  Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.

Authors:  Martin Block; Carsten Gründker; Stefanie Fister; Julia Kubin; Ludwig Wilkens; Michael D Mueller; Bernhard Hemmerlein; Günter Emons; Andreas R Günthert
Journal:  Int J Oncol       Date:  2012-08-21       Impact factor: 5.650

5.  EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.

Authors:  Yisun Jeong; Soo Youn Bae; Daeun You; Seung Pil Jung; Hee Jun Choi; Isaac Kim; Se Kyung Lee; Jonghan Yu; Seok Won Kim; Jeong Eon Lee; Sangmin Kim; Seok Jin Nam
Journal:  Cell Physiol Biochem       Date:  2019

6.  ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway.

Authors:  Guangliang Li; Jing Zhang; Zhenzhen Xu; Zhongqi Li
Journal:  Cancer Manag Res       Date:  2020-01-14       Impact factor: 3.989

7.  Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.

Authors:  Scott Thomas; K Ted Thurn; Paromita Raha; Stephanie Chen; Pamela N Munster
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

Review 8.  Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.

Authors:  Sarah R Hosford; Todd W Miller
Journal:  Pharmgenomics Pers Med       Date:  2014-08-06

9.  Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms.

Authors:  Songyin Huang; Yang Chen; Zhi-Mei Liang; Na-Na Li; Yujie Liu; Yinghua Zhu; Dingzhun Liao; Xiao Zhen Zhou; Kun Ping Lu; Yandan Yao; Man-Li Luo
Journal:  Front Cell Dev Biol       Date:  2019-12-06

10.  Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.

Authors:  Dongbo Li; Hongfei Ji; Xingjian Niu; Lei Yin; Yiran Wang; Yucui Gu; Jinlu Wang; Xiaoping Zhou; Han Zhang; Qingyuan Zhang
Journal:  Cancer Sci       Date:  2019-12-19       Impact factor: 6.716

View more
  13 in total

1.  FoxO3a Inhibits Tamoxifen-Resistant Breast Cancer Progression by Inducing Integrin α5 Expression.

Authors:  Elena Ricci; Mariarosa Fava; Pietro Rizza; Michele Pellegrino; Daniela Bonofiglio; Ivan Casaburi; Marilena Lanzino; Cinzia Giordano; Rosalinda Bruno; Rosa Sirianni; Ines Barone; Diego Sisci; Catia Morelli
Journal:  Cancers (Basel)       Date:  2022-01-02       Impact factor: 6.639

Review 2.  Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer.

Authors:  Ho Tsoi; Chan-Ping You; Man-Hong Leung; Ellen P S Man; Ui-Soon Khoo
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

3.  Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates.

Authors:  Foster Birnbaum; Asuka Eguchi; Gaspard Pardon; Alex C Y Chang; Helen M Blau
Journal:  NPJ Regen Med       Date:  2022-03-18

Review 4.  Common Multiple Primary Cancers Associated With Breast and Gynecologic Cancers and Their Risk Factors, Pathogenesis, Treatment and Prognosis: A Review.

Authors:  Shuwen Ge; Bo Wang; Zihao Wang; Junjian He; Xiaoxin Ma
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 5.  Spotlight on Exosomal Non-Coding RNAs in Breast Cancer: An In Silico Analysis to Identify Potential lncRNA/circRNA-miRNA-Target Axis.

Authors:  Ohanes Ashekyan; Samira Abdallah; Ayman Al Shoukari; Ghada Chamandi; Hayat Choubassy; Abdul Rahman S Itani; Nisreen Alwan; Rihab Nasr
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

Review 6.  The role of CircRNA/miRNA/mRNA axis in breast cancer drug resistance.

Authors:  Mohammad H Ghazimoradi; Sadegh Babashah
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

7.  The E3 Ligase TRIM4 Facilitates SET Ubiquitin-Mediated Degradation to Enhance ER-α Action in Breast Cancer.

Authors:  Dianwen Han; Lijuan Wang; Li Long; Peng Su; Dan Luo; Hanwen Zhang; Zheng Li; Bing Chen; Wenjing Zhao; Ning Zhang; Xiaolong Wang; Yiran Liang; Yaming Li; Guohong Hu; Qifeng Yang
Journal:  Adv Sci (Weinh)       Date:  2022-07-17       Impact factor: 17.521

8.  Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer.

Authors:  Ho Tsoi; Ling Shi; Man-Hong Leung; Ellen P S Man; Zi-Qing So; Wing-Lok Chan; Ui-Soon Khoo
Journal:  Life (Basel)       Date:  2022-01-10

9.  Identification of key genes involved in tamoxifen-resistant breast cancer using bioinformatics analysis.

Authors:  Xiaopeng Wang; Shixia Wang
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

10.  Discovery of Proteins Responsible for Resistance to Three Chemotherapy Drugs in Breast Cancer Cells Using Proteomics and Bioinformatics Analysis.

Authors:  Hyo Kyeong Cha; Seongmin Cheon; Hyeyoon Kim; Kyung-Min Lee; Han Suk Ryu; Dohyun Han
Journal:  Molecules       Date:  2022-03-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.